Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)

Trial Profile

A Phase 1/1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs KSI 301 (Primary)
  • Indications Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Kodiak Sciences
  • Most Recent Events

    • 08 Feb 2019 According to a Kodiak Sciences media release, an update about the trial will be presented at the Angiogenesis, Exudation, and Degeneration 2019 meeting being held on February 9, 2019 in Miami, FL.
    • 31 Dec 2018 Status changed from planning to recruiting.
    • 03 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top